The immuno-oncology assays market is a rapidly advancing segment of the global life sciences and diagnostics industry, playing a pivotal role in cancer research, drug development, and personalized medicine. Immuno-oncology assays are analytical tools used to evaluate immune responses against cancer, supporting the development and clinical application of immunotherapies such as checkpoint inhibitors, cancer vaccines, and cell-based therapies. According to Straits Research, the growing focus on precision oncology, expanding immunotherapy pipelines, and increasing cancer prevalence are driving strong growth in the immuno-oncology assays market.

Market Size 2024 – USD 5.24 Billion · Market Size 2025 – USD 5.79 Billion · Market Size 2033 – USD 12.36 Billion · CAGR (2023–2031) – 10.4%

Get Your Sample Report Here: https://straitsresearch.com/report/immuno-oncology-assays-market/request-sample
Buy Report Now: https://straitsresearch.com/buy-now/immuno-oncology-assays-market
Download full report: https://straitsresearch.com/report/immuno-oncology-assays-market

Market Overview

Immuno-oncology assays are essential for understanding tumor–immune system interactions and evaluating biomarkers that predict therapeutic response. These assays are widely used in preclinical research, clinical trials, and companion diagnostics to assess immune activation, tumor microenvironment, and treatment efficacy. Straits Research states that the global immuno-oncology assays market size was valued at USD 4.11 billion in 2022 and is projected to reach USD 10.02 billion by 2031, reflecting the growing adoption of immunotherapy-based cancer treatments.

The market is expanding as pharmaceutical and biotechnology companies intensify investments in immuno-oncology drug development. In parallel, academic and research institutions are increasingly using advanced assay platforms to accelerate cancer research and translational studies.

Market Drivers and Challenges

Key Market Drivers

Rising prevalence of cancer worldwide
The increasing global burden of cancer is a primary driver for immuno-oncology research. Immunotherapies are becoming a cornerstone of cancer treatment, significantly increasing demand for assays that support biomarker discovery and therapy monitoring.

Growth of immunotherapy drug pipelines
Pharmaceutical and biotechnology companies are expanding their immuno-oncology pipelines, leading to higher demand for validated and high-throughput assays across drug discovery and clinical development stages.

Advancements in assay technologies
Technological progress in multiplex assays, flow cytometry, next-generation sequencing, and immunohistochemistry has enhanced assay sensitivity, accuracy, and scalability. These innovations are driving broader adoption across research and clinical settings.

Market Challenges

High cost of advanced assay platforms
Sophisticated immuno-oncology assays require expensive instruments, reagents, and skilled personnel, which can limit adoption in cost-sensitive laboratories and emerging markets.

Complexity of immune response analysis
Cancer–immune system interactions are highly complex, requiring precise assay design and interpretation. Variability in biological samples and lack of standardized protocols can pose challenges for consistent results.

Market Segmentation Analysis

By Product Type

The immuno-oncology assays market is segmented into reagents and kits, instruments, and software and services. Reagents and kits account for the largest share due to recurring demand in research and clinical applications. Instruments such as flow cytometers and imaging systems support advanced assay execution, while software solutions are gaining importance for data analysis and interpretation.

By Technology

Based on technology, the market includes flow cytometry, immunohistochemistry, enzyme-linked immunosorbent assay, polymerase chain reaction, and sequencing-based assays. Flow cytometry holds a significant share due to its ability to analyze immune cell populations with high precision. Immunohistochemistry is widely used for biomarker detection in tissue samples.

By Application

Drug discovery and development
Immuno-oncology assays are extensively used in drug discovery to identify targets, screen compounds, and evaluate immune responses during preclinical and clinical trials.

Clinical diagnostics
In clinical diagnostics, these assays support patient stratification, therapy selection, and treatment monitoring, particularly for immune checkpoint inhibitors.

Academic and research applications
Academic and research institutions use immuno-oncology assays to study tumor biology, immune mechanisms, and novel therapeutic approaches.

By End User

End users include pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations. Pharmaceutical and biotechnology companies dominate the market due to extensive immunotherapy research activities and large-scale clinical trials.

By Region

North America leads the immuno-oncology assays market due to strong research infrastructure, high cancer research funding, and presence of leading pharmaceutical companies. Europe follows, supported by active clinical research and government initiatives in oncology. Asia-Pacific is expected to witness the fastest growth, driven by expanding biopharmaceutical industries, increasing cancer incidence, and growing investment in research infrastructure.

Top Players Analysis

According to Straits Research, the immuno-oncology assays market is competitive, with key players focusing on assay innovation, portfolio expansion, and strategic collaborations.

1. Thermo Fisher Scientific Inc.
   Thermo Fisher Scientific offers a broad range of immuno-oncology assay kits, reagents, and analytical platforms supporting cancer research and drug development.

2. Becton, Dickinson and Company
   BD provides advanced flow cytometry systems and reagents widely used in immuno-oncology research and immune profiling.

3. Agilent Technologies, Inc.
   Agilent specializes in immunohistochemistry and molecular pathology solutions that support biomarker analysis in oncology.

4. Merck KGaA
   Merck supplies high-quality reagents and assay solutions for immunology and oncology research, supporting translational studies.

5. PerkinElmer, Inc.
   PerkinElmer offers multiplex assay technologies and imaging solutions used in immuno-oncology research and clinical studies.

Related FAQs

What are immuno-oncology assays used for?
They are used to study immune responses to cancer, support immunotherapy development, and identify predictive biomarkers.

Why is the immuno-oncology assays market growing?
The market is growing due to rising cancer prevalence, expanding immunotherapy pipelines, and advancements in assay technologies.

Which region dominates the immuno-oncology assays market?
North America dominates the market, while Asia-Pacific is expected to grow at the fastest rate.

About Us

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.